AMIX - AMIX

Ultime notizie per Autonomix Medical (NASDAQ:AMIX) Azioni

Autonomix Medical

Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

Evercore ISI Group analyst Elizabeth Anderson maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Outperform and raises the price target from $760 to $800.

News

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $800

Evercore ISI Group analyst Elizabeth Anderson maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Outperform and raises the price target from $260 to $285.

Laboratory Corporation Of America Holdings

Evercore ISI Group Maintains Outperform on Labcorp Hldgs, Raises Price Target to $285

RBC Capital analyst Scott Hanold maintains Tamboran Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBN#NYSE">TBN</a>) with a Sector Perform and lowers the price target from $31 to $30.

RBC Capital Maintains Sector Perform on Tamboran Resources, Lowers Price Target to $30

Evercore ISI Group analyst Elizabeth Anderson maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and raises the price target from $170 to $180.

Evercore ISI Group Maintains Outperform on IQVIA Hldgs, Raises Price Target to $180

Evercore ISI Group analyst Ross Muken maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and raises the price target from $155 to $170.

ICLR

Evercore ISI Group Maintains Outperform on Icon, Raises Price Target to $170

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) with a Outperform and lowers the price target from $57 to $30.

IDYA

RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $30

Cryptocurrency markets are trading modestly higher on Wednesday morning as markets await further tariff announcements by President Trump.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$109,110.29</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,628.26</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$154.09</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.38</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1736</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001199</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transcation decreased by 15.1% and 21.4%, respectively. Daily active addresses are up by 13.5% and 0.8%, respectively.</li>
<li>Coinglass data shows 68,688 traders were liquidated in the past 24 hours for $138.76 million.</li>
<li>SoSoValue data shows net inflows of $80 million into spot Bitcoin ETFs on Monday, while spot Ethereum ETFs saw net inflows of $46.6 million.</li>
</ul>
Trader Notes: Crypto trader BitBull <a href="https://x.com/AkaBull_/status/1942881621335580899">spotted </a>a potential inverse head and shoulders pattern on both the 3-day BTC chart and RSI.
He says confirmation requires either a 3-day candle close above $110,000 or RSI closing above 70. If confirmed, BTC could enter a 3–4 week &#8220;up-only&#8221; rally.
Crypto trader Momin flagged that Bitcoin dominance slipping below 65% could mark a shift to an altcoin-led rally, especially if the daily close confirms. 
With Ethereum showing strength and exchange supply drying up, he concluded, "A new rally likely incoming soon!"
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin dominance under 65%!!! Its happening, just want the daily close to confirm it!<a href="https://twitter.com/search?q=%24ETH&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ETH</a> already showing strength! Combined with supply dried up on exchanges! A new rally likely incoming soon! Are we ready to cook? <a href="https://t.co/AjzgNwXwiM">https://t.co/AjzgNwXwiM</a> <a href="https://t.co/ERUnqwwcKh">pic.twitter.com/ERUnqwwcKh</a>
&mdash; Momin (@mominsaqib) <a href="https://twitter.com/mominsaqib/status/1942890220745314596?ref_src=twsrc%5Etfw">July 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Follis <a href="https://x.com/follis_/status/1942669622618251480">sees </a>a clean range developing in Solana and is watching for long entries on sweeps of the range low. For Ethereum, he <a href="https://x.com/follis_/status/1942664361312465322">also</a> notes a clean setup but advises that high-probability trades lie at the extremes of the current range.
DonAlt highlighted XRP coiling beneath resistance. He notes that if it doesn't break out soon, XRP could remain range-bound for another 1–2 months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> Is this finally gonna be the breakout or are we gonna have to wait another month or two? <a href="https://t.co/KhAHov9wno">pic.twitter.com/KhAHov9wno</a>
&mdash; DonAlt (@CryptoDonAlt) <a href="https://twitter.com/CryptoDonAlt/status/1942893658962788565?ref_src=twsrc%5Etfw">July 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
For Dogecoin, Hardy <a href="https://x.com/Degen_Hardy/status/1942865993157722151">pointed</a> out that $15 billion in liquidations are stacked between $0.17–$0.19. A move above this zone could trigger a massive, short squeeze with major upside potential.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46304975/bitcoin-robinhood-coinbase-surged-30-to-100-in-q2-whats-next">Bitcoin, Robinhood, Coinbase Surged 30% To 100% In Q2: What&#8217;s Next?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin Stalls Around $109,000 While Ethereum, XRP, Dogecoin Edge Higher

Wells Fargo analyst Larry Biegelsen downgrades RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) from Overweight to Equal-Weight and lowers the price target from $25 to $9.

Downgrades

RXST

Wells Fargo Downgrades RxSight to Equal-Weight, Lowers Price Target to $9

RBC Capital analyst Irene Nattel maintains Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) with a Sector Perform and raises the price target from $468 to $542.

CASY

RBC Capital Maintains Sector Perform on Casey's General Stores, Raises Price Target to $542

Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a In-Line and lowers the price target from $5 to $4.

HCAT

Evercore ISI Group Maintains In-Line on Health Catalyst, Lowers Price Target to $4

Evercore ISI Group analyst Elizabeth Anderson maintains Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) with a In-Line and lowers the price target from $6 to $5.

FTRE

Evercore ISI Group Maintains In-Line on Fortrea Holdings, Lowers Price Target to $5

RBC Capital analyst Ben Hendrix reiterates Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) with a Outperform and maintains $9 price target.

Reiteration

RBC Capital Reiterates Outperform on Brookdale Senior Living, Maintains $9 Price Target

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) with a Outperform and raises the price target from $170 to $180.

Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $180

Evercore ISI Group analyst Stephen Richardson maintains AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) with a Outperform and raises the price target from $90 to $108.

Evercore ISI Group Maintains Outperform on AZZ, Raises Price Target to $108

Evercore ISI Group maintains Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Outperform and raises the price target from $200 to $220.

ALGN

Evercore ISI Group Maintains Outperform on Align Technology, Raises Price Target to $220

JMP Securities analyst Chris Muller reiterates Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) from Market Perform to Market Perform.

SACH

JMP Securities Reiterates Market Perform on Sachem Capto Market Perform

Fourth Quarter Fiscal Year 2025 Financial Results to be Released on Thursday, August 7, 2025
Company Reports Strong Preliminary Q4FY25 Revenue Expectations of&nbsp;approximately US$1.31 Billion
WATERLOO, ON, July 9, 2025 /PRNewswire/ --&nbsp;Open Text Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>), (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#TSX">OTEX</a>) announced today that Chadwick Westlake will step down as EVP, Chief Financial Officer to assume the President &amp; Chief Executive Officer role at his former employer, EQB, following the unexpected passing of its CEO. Mr. Westlake's departure will be effective August 15, 2025, post-completion of OpenText's fiscal year-end reporting.
OpenText has initiated a comprehensive search to identify a long-term successor with the assistance of a leading executive search firm. Following Mr. Westlake's departure in August and until the search is completed, Cosmin Balota, OpenText's SVP, Chief Accounting Officer, will serve as CFO on an interim basis.&nbsp; Mr. Balota has over 30 years of experience, joined OpenText in 2019, and is a Chartered Professional Accountant in Canada and holds a Master of Accounting from the University of Waterloo.

Guidance

Management

OTEX

TSX:OTEX

OpenText CFO Chadwick Westlake To Depart, Cosmin Balota Appointed Interim CFO; Preliminary Q4 Revenue Expectations Of ~$1.31B

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are trading relatively flat in the<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> premarket session on Tuesday.</a>
The company has teamed up with Tomorrow.io, a weather analytics and resilience firm, to bring AI-driven weather insights into its suite of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46314920/palantir-and-tomorrow-io-partner-to-operationalize-global-weather-intelligence-and-agentic-ai" rel="noreferrer noopener">decision-making platforms.</a>
The collaboration targets improved operational readiness for clients in defense, aviation, government, and infrastructure by embedding real-time atmospheric data and predictive tools directly into Palantir's systems.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/biotech/25/07/46289610/palantir-co-founder-joe-lonsdale-wants-a-fda-overhaul-with-special-forces-style-ai-team-because-china-is-racing-to-outpace-us-in-biotech" rel="noreferrer noopener">Palantir Co-Founder Joe Lonsdale Wants A FDA Overhaul With Special Forces-Style AI Team Because China Is Racing To Outpace US In Biotech</a>
The companies aim to offer fully automated, weather-aware workflows by integrating Tomorrow.io's proprietary satellite constellation and machine learning capabilities with Palantir's operational AI.
The effort will pursue joint commercial and government opportunities across sectors.
Tomorrow.io has launched the first private weather satellite network specifically designed for atmospheric observation.
Its adaptive AI models learn from each data cycle, making hyper-local, minute-by-minute forecasts possible.
By embedding these capabilities into Palantir's platforms, the joint solution aims to help users automate critical decisions—like rerouting logistics or activating emergency protocols—based on real-time weather intelligence.
As part of the arrangement, Tomorrow.io will join Palantir's FedStart initiative.
This program enables SaaS providers to rapidly enter the federal marketplace by supporting FedRAMP and IL compliance, thereby providing them access to U.S. government agencies.
Other recent FedStart partners include Anthropic, Grafana Labs, and Virtualitics.
Mike Gallagher, Palantir's Head of Defense, said the goal of FedStart is to accelerate the government&#8217;s ability to access and deploy breakthrough technologies.
"By&nbsp;enabling the federal workforce to take advantage of&nbsp;Tomorrow.io&nbsp;while ensuring strict adherence to the compliance and security&nbsp;requirements for processing U.S. government (USG) data, we are excited to help increase productivity and efficacy across&nbsp;government," Gallagher said.
Shimon Elkabetz, CEO and co-founder of Tomorrow.io, highlighted the strategic importance of the partnership. "In the age of AI, whoever owns the data owns the future," Elkabetz said. "As the only full-stack weather company with proprietary data from space, operational-grade AI modeling and agentic intelligence, we are defining the next generation of decision-making and competitive advantage with a truly synergetic partner in Palantir."
With this collaboration, the two companies plan to create tailored solutions for both public and private clients, setting a new global benchmark in resilience and real-time, data-driven action.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLTR stock has gained over 410% in the past year. Investors can gain exposure to the stock via GraniteShares 2x Long PLTR Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIR#NASDAQ">PTIR</a>).
Price Action: PLTR shares are trading lower by 0.15% to $139.50 premarket at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/07/46301128/investor-used-to-believe-they-could-beat-the-market-by-picking-stocks-now-they-ask-is-holding-individual-stocks-worth-the-stress-anymore" target="_blank" rel="noreferrer noopener">Investor Used To Believe They Could Beat The Market By Picking Stocks. Now They Ask &#8216;Is Holding Individual Stocks Worth The Stress Anymore?&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Movers

General

PLTR

PTIR

This Palantir Partnership Uses AI And Satellites To Predict Weather Like Never Before - Here's What It Means

Evercore ISI Group analyst Elizabeth Anderson maintains Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) with a In-Line and lowers the price target from $5 to $3.

Evercore ISI Group Maintains In-Line on Agilon Health, Lowers Price Target to $3

- Alpha Modus Holdings, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/AMOD#NASDAQ">AMOD</a>), a pioneer in AI-powered retail technology and data-driven innovation, is pleased to announce the issuance of U.S. Patent No. 12,354,121, effective July 8, 2025. This patent strengthens Alpha Modus's intellectual property position in the fast-evolving in-store technology space, particularly in areas related to real-time shopper engagement, digital signage, and autonomous retail optimization.
The patent, co-invented by Alpha Modus Director Michael Garel and Jim Wang, underscores the company's long-term commitment to advancing retail intelligence platforms that bridge the gap between physical stores and AI-driven decisioning engines.

AMOD

Alpha Modus Holdings Secures U.S. Patent No. 12,354,121 To Enhance AI-Powered Retail Technology For Real-Time Shopper Engagement And Autonomous Store Optimization

Press Releases

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

AMIX

Aethlon Medical

Bluejay Diagnostics

Biomerica

Co-Diagnostics

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

INVO Fertility

NanoVibronix

ENDRA Life Sciences

PAVmed

Predictive Oncology

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences

SINTX Technologies

Tivic Health Systems, Inc. - Common stock

Comments

Autonomix Medical

Notizie

Ultime notizie per Autonomix Medical (NASDAQ:AMIX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO